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Pseudoxanthoma elasticum (PXE), a prototypic heritable disorder with ectopic mineralization, manifests with
characteristic skin findings, ocular involvement and cardiovascular problems, with considerable morbidity and
mortality. The classic forms of PXE are due to loss-of-function mutations in the ABCC6 gene, which encodes
ABCC6, a transmembrane efflux transporter expressed primarily in the liver. Several lines of evidence suggest
that PXE is a primary metabolic disorder, which in the absence of ABCC6 transporter activity, displays reduced
plasma anti-mineralization capacity due to reduced fetuin-A and matrix gla-protein (MGP) levels. MGP requires
to be activated by g-glutamyl carboxylation, a vitamin K–dependent reaction, to serve in an anti-mineralization
role in the peripheral connective tissue cells. Although the molecules transported from the hepatocytes to
circulation by ABCC6 in vivo remain unidentified, it has been hypothesized that a critical vitamin K derivative,
such as reduced vitamin K conjugated with glutathione, is secreted to circulation physiologically, but not in the
absence of ABCC6 transporter activity. As a result, activation of MGP by g-glutamyl carboxylase is diminished,
allowing slow yet progressive mineralization of connective tissues characteristic of PXE. Understanding of the
pathomechanistic details of PXE provides a basis for the development of targeted molecular therapies for this
currently intractable disease.
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PXE: THE DIAGNOSTIC CHALLENGE
Pseudoxanthoma elasticum (PXE), a
multi-system heritable disorder charac-
terized by ectopic mineralization of
soft connective tissues, can pose a
diagnostic challenge to practitioners,
for several reasons (Neldner, 1988).
From the historical perspective, the
original descriptions of cutaneous man-
ifestations in PXE, in association with
elastic degeneration of the skin and
heart, were given by French dermatol-
ogists under the general diagnosis
of ‘‘xanthelasma’’ (Balzer, 1884;
Chauffard, 1889). Subsequently, after
extensive re-examination of the pre-
viously published cases, Darier, in
1896, proposed the name ‘‘pseudo-
xanthome elastique´’’ to differenti-
ate this condition from xanthomas,
hence ‘‘pseudoxanthoma’’ (Darier,
1896). In the late 1920s, Gro¨nblad
and Strandberg, an ophthalmologist
and a dermatologist, both from Swe-
den, recognized the association of the
characteristic skin manifestation with
angioid streaks, thus establishing the
eponym Gro¨nblad–Strandberg Syn-
drome (Gro¨nblad, 1929; Strandberg,
1929). The cardiovascular manifesta-
tions of PXE were not fully appreciated
until some two decades later (Carlborg,
1944). More recently, identification of
the gene defects underlying PXE has
helped to clarify the clinical constella-
tions and molecular genetics of this
disorder (Chassaing et al., 2005;
Miksch et al., 2005; Li et al., 2009a).
PXE is an autosomal recessive dis-
order, but its precise prevalence is
currently unknown. The estimates vary
widely, but those in the range of 1
in 50,000–70,000 may be represen-
tative of the actual value. PXE is
encountered in all ancestral back-
grounds without racial predilection. In
some areas (such as South Africa) the
prevalence may be higher because of
consanguinity and/or the presence of a
founder effect (Le Saux et al., 2002;
Ramsay et al., 2009). There appears to
be a slight female preponderance, but
the reasons for this phenomenon in an
autosomal recessive disease with appar-
ently full penetrance are not clear.
Furthermore, adding to the diagnostic
difficulty is that the clinical findings of
PXE are rarely present at birth and the
skin findings usually become recogniz-
able not until during the second or third
decade of life (Neldner, 1988; Pfendner
et al., 2007; Naorui et al., 2009; Li et al.,
2009a). In many cases, the accurate
diagnosis is not made until serious
ocular or vascular complications devel-
op in the third or fourth decade of life.
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PHENOTYPIC SPECTRUM OF PXE
PXE is characterized by dystrophic
mineralization of soft connective
tissues in a number of organs, but the
primary clinical manifestations in clas-
sic PXE center on three major organ
systems, viz., the skin, the eyes, and the
cardiovascular system (Neldner, 1988).
Skin manifestations
The primary cutaneous lesions are
small, discrete yellowish papules that
appear initially in the flexural areas,
including lateral neck, antecubital and
popiliteal fossae. These primary lesions
coalesce into larger plaques of inelastic
and leathery skin, which progressively
extends to involve non-flexural sites as
well. In most extensive cases, essen-
tially all skin can be involved with loss
of elasticity and recoil. Mucosal mem-
branes, particularly the inner lower lip,
can become involved in a similar
manner with yellow papules. The
cutaneous findings present primarily a
cosmetic problem and do not interfere
with normal life activities. However,
the presence of characteristic skin
lesions signifies the risk for develop-
ment of ocular and vascular complica-
tions that can be quite debilitating
with considerable morbidity and even
mortality.
Eye findings
The characteristic ophthalmologic find-
ing in the majority of patients with PXE
is angioid streaks, and after the age of
30 years their prevalence approaches
100 percent (Neldner, 1988). Although
angioid streaks may be detected in
some cases as early as in the first
decade of life, they frequently become
symptomatic later in life, particularly
after trauma to the eye. Angioid streaks
derive from breaks upon aberrant
mineralization of the elastic lamina of
Bruch’s membrane, which separates
the pigmented layer of the retina from
the choroid of the eye. These fractures
can lead to neovascularization from
choriocapillaries, and subsequent leak-
age of newly formed vessels leads to
hemorrhage and scarring (Georgalas
et al., 2009). Ultimately, these patho-
logic changes cause progressive loss of
visual acuity and, relatively rarely, in
central blindness. It should be noted,
however, that angioid streaks, although
characteristic for PXE, are not pathog-
nomonic (Neldner, 1988). They can be
encountered in a variety of metabolic
and heritable disorders as well as in the
setting of age-associated degenerative
changes of the Bruch’s membrane
(Georgalas et al., 2009).
Cardiovascular involvement
PXE affects the cardiovascular system
primarily by mineralization of mid-
sized arteries of the extremities where
progressive calcification of the elastic
media and intima inflicts the vessel
damage (Mendelsohn et al., 1978;
Kornet et al., 2004). As a result of these
changes, clinical manifestations, in-
cluding intermittent claudication, loss
of peripheral pulses, reno-vascular hy-
pertension, angina pectoris, and rarely,
myocardial infarction, can result. There
is an increased risk for cerebral is-
chemic attacks, and mineralized blood
vessels of the gastric and intestinal
mucosa can rupture leading to gastro-
intestinal bleeding (Goral et al., 2007).
The vascular symptoms can cause
significant morbidity and may even
result in premature demise of the
affected individual. Risk for cardiovas-
cular complications is somewhat in-
creased during pregnancy and labor. It
should be noted, however, that in spite
of extensive mineralization of placenta,
PXE is not associated with markedly
increased fetal loss or adverse obste-
trical outcomes (Bercovitch et al.,
2004; Tan and Rodeck, 2008). Thus,
with appropriate counseling, there is
no basis for advising women with PXE
to avoid becoming pregnant.
Although in most severe cases PXE is
associated with considerable morbidity
and occasional mortality from cardio-
vascular complications, the phenotypic
spectrum of this disease is highly
variable, with both inter- and intra-
familial heterogeneity (Neldner, 1988;
Sakata et al., 2006; Li et al., 2009a). In
some families, involvement of a given
organ system may be predominant, so
that in some families the major findings
are in the skin, whereas in other
families the ocular findings predomi-
nate with little skin involvement. In
other families, cardiovascular symp-
toms may be the major cause of
morbidity, with relatively little skin or
eye involvement.
The mode of inheritance
Adding to the complexity and diagnos-
tic challenge of PXE were early sugges-
tions that both autosomal dominant
and autosomal recessive forms of the
disease exist (Pope, 1975). Recent
advances of molecular genetics have
established that PXE is exclusively an
autosomal recessive disorder (Plomp
et al., 2004; Ringpfeil et al., 2006).
The early suggestions of the presence of
autosomal dominant forms were based
on clinical findings, mostly cutaneous,
in individuals in two subsequent gen-
erations in some families, but this can
in most cases be explained on the basis
of pseudo-dominance, often as a result
of familial consanguinity (Chassaing
et al., 2004; Ringpfeil et al., 2000,
2006). It should be noted that there are
no fully documented reports of PXE in
three subsequent generations, refuting
the existence of classic Mendelian
autosomal dominant inheritance. Ob-
ligate heterozygote carriers have essen-
tially normal or very limited clinical
phenotype but some cases have been
reported to show microscopic changes
of mineralization in the elastic fibers
(Martin et al., 2007). A recent study has
suggested that heterozygous carriers
may occasionally have serious mani-
festations, particularly affecting the
eyes (Martin et al., 2008). The carrier
individuals may also be at increased
risk for premature coronary artery dis-
ease (Trip et al., 2002). These observa-
tions may suggest a role for modifying
genes or environmental factors in the
mineralization processes.
MOLECULAR GENETICS OF PXE
Because the primary histopathology of
the skin in PXE was noted to involve
elastic fibers, the genes participating in
the synthesis and assembly of the
elastic fiber network were initially
considered as a candidate gene/protein
system for mutations in this disease.
These included elastin on chromosome
7q, the elastin-associated microfibrillar
proteins, such as fibrillin-1 and fibrillin-
2 (FBN1 and FBN2) on chromosomes
15 and 5, and lysyloxidase, also on
chromosome 15. However, with the
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cloning of the corresponding genes,
genetic linkage analyses excluded
these chromosomal regions as the sites
of PXE-associated genes (Christiano
et al., 1992; Raybould et al., 1994).
Subsequently, the positional cloning
approaches provided strong evidence
for linkage to the short-arm of chromo-
some 16, and refinement of the critical
interval focused on an B500 kb region
that contained four genes, none of
which had an obvious connection to
the extracellular matrix of connective
tissues in general or to the elastic fiber
network in particular (Le Saux et al.,
1999; Cai et al., 2000). Systematic
sequencing of these candidate genes
resulted in identification of the ABCC6
gene as the one harboring mutations in
PXE (Bergen et al., 2000; Le Saux et al.,
2000; Ringpfeil et al., 2000; Struk
et al., 2000). This gene consists of 31
exons spanning approximately 75 kb of
the human genome on chromosomal
region 16p13.1 This region also
contains two closely related, yet non-
functional, 50-pseudogenes, which cor-
respond to exons 1–9 and 1–4 of the
coding gene, respectively (Pulkkinen
et al., 2001). A close sequence similar-
ity (over 99%) between the two
pseudogenes and the coding gene
complicates mutation detection at the
50-end of the gene, although allele-
specific primer sets have been designed
for each exon of the coding gene, thus
facilitating analysis without interfer-
ence from the pseudogene sequences
(Pfendner et al., 2007).
The ABCC6 gene/protein system
The ABCC6 gene is transcribed into an
approximately 5 kb mRNA, and trans-
lated into a 165 kDa protein of 1,503
amino acids. This protein, ABCC6 (also
known as multi-drug resistance-asso-
ciated protein 6, is a member of the
C-family of ATP-binding cassette (ABC)
proteins (Borst and Elferink, 2002).
ABCC6 has three hydrophobic trans-
membrane domains consisting of 5, 6
and 6 transmembrane helices, as well
as two intracellular nucleotide-binding
folds with highly conserved Walker
motifs and ABC signature that are
critical for the function of the protein
in ATP-driven transmembrane transpor-
ters (Szaka´cs et al., 2008). On the basis
of sequence homology with other
members of the C-family of the ABC
proteins, particularly the prototype
ABCC1, the ABCC6 has been postu-
lated to function as an efflux transpor-
ter, and it has been shown to transport
polyanionic, glutathione-conjugated
molecules in an in vitro inside–out
vesicle system (Belinsky et al., 2002;
Ilia´s et al., 2002). The precise role of
ABCC6 and the substrate specificity of
this putative transporter in vivo are
currently unknown. Nevertheless, the
critical role of the ABCC6 gene in the
pathogenesis of PXE has been con-
firmed by the development of trans-
genic mice through targeted ablation
of the corresponding mouse gene
(Gorgels et al., 2005; Klement et al.,
2005). The Abcc6/ mice recapitulate
the genetic, histopathological and ultra-
structural findings in patients with PXE,
including progressive mineralization
of connective tissues (Klement et al.,
2005; Jiang et al., 2007). Moreover, an
alternative splice variant in Abcc6,
leading to a 5-bp deletion, has been
identified in dystrophic cardiac calcifi-
cation susceptible mouse strain C3H/
He, DBA/2J, and 1295S/SvJ; but not in
dystrophic cardiac calcification-resis-
tant mouse C57BL/6, attesting to the
role of the Abcc6 gene in mineralization
processes (Aherrahrou et al., 2008).
ABCC6 mutations in PXE
Well over 300 distinct mutations re-
presenting over 1000 mutant alleles
have been encountered in the ABCC6
gene in patients with PXE (Miksch
et al., 2005; Pfendner et al., 2007,
2008; Li et al., 2009a). The types of
mutations include missense and non-
sense mutations in 28 of the 31 exons
of ABCC6, intronic mutations causing
mis-splicing, small deletions or inser-
tions resulting in frame shift of transla-
tion, as well as large deletions spanning
part or the entire coding region of the
gene and sometimes including flanking
genes as well (Chassaing et al., 2007).
Two recurrent mutations of high fre-
quency have been identified: p.R1141X
in exon 24 is the most common,
particularly in Caucasian individuals,
with a prevalence of approximately
30% of all pathologic PXE mutations
(Pfendner et al., 2007). In addition, a
recurrent AluI-mediated deletion of
exons 23–29 (del23–29; p.A999-
S1403del) has been found at least in
one allele in up to 20% in US and 12%
of European patients (Ringpfeil et al.,
2001; Chassaing et al., 2004; Pfendner
et al., 2007). Identification of addi-
tional recurrent nonsense mutations, as
well as clustering of the missense
mutations to exons 24 and 28, which
code for the nucleotide-binding folds
and on the domain–domain interfaces,
have allowed the development of
streamlined mutation detection strate-
gies, with the overall detection rate of
up to 99% (Hu et al., 2004; Pfendner
et al., 2007; Fu¨lo¨p et al., 2009). Thus,
mutation analysis is now readily avail-
able for individuals suspected to have
or to be at risk for PXE. As in the case of
other heritable disorders with extensive
mutation database, identification of
mutations in the ABCC6 gene can be
used for confirmation of the clinical
diagnosis, carrier detection and pre-
symptomatic identification of affected
individuals. Although no specific treat-
ment is presently available for PXE,
early identification of the disease and
increased surveillance for its sequela
will undoubtedly improve the quality
of life of the affected individuals.
PUTATIVE PATHOMECHANISMS
OF PXE
Histopathologic evaluation of skin and
other affected tissues in PXE reveals
progressive mineralization of connec-
tive tissues, particularly elastic struc-
tures, as the characteristic feature, and
accumulation of calcium/phosphate in
these lesions is apparently responsible
for clinical manifestations in the skin,
the eyes, and the cardiovascular sys-
tem. As indicated above, the classic
forms of PXE are caused by mutations
in the ABCC6 gene, a putative efflux
transporter. One of the early surprising
observations was that this gene is
primarily expressed in the liver, to a
lesser extent in the proximal tubules of
kidneys, and at very low level, if at all,
in tissues clinically affected in PXE
(Belinsky and Kruh, 1999; Scheffer
et al., 2002; Jiang et al., 2006). These
observations raised an apparent dilem-
ma concerning the pathomechanisms
of PXE. Specifically, how do mutations
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in the gene expressed primarily in the
liver result in mineralization of con-
nective tissues in the skin, the eyes, and
the blood vessels? To explain the
potential mechanisms leading from
ABCC6 mutations to ectopic minerali-
zation in peripheral connective tissues
in PXE, at least two general theories
have been advanced. The ‘‘metabolic
hypothesis’’ (Uitto et al., 2001) postu-
lates that absence of ABCC6 activity
primarily in the liver results in the
deficiency of circulating factors that
are physiologically required to prevent
aberrant mineralization under normal
calcium and phosphate homeostatic
conditions (Figure 1) (Li et al., 2009a).
This postulate is predicated on previous
identification of a number of proteins,
which serve as powerful anti-minerali-
zation molecules in the circulation,
including fetuin-A, matrix gla-protein
(MGP), and ankylosis protein (Jahnen-
Dechent et al., 1997; Luo et al., 1997;
Ryan, 2001). The ‘‘PXE cell hypoth-
esis’’ postulates that lack of ABCC6
expression in the resident cells in
clinically affected tissues, such as in
skin fibroblasts or arterial smooth
muscle cells, alters the biosynthetic
expression profile and cell–cell and
cell–matrix interactions, associated
with changes in the proliferative capa-
city of these cells. Specifically, cultured
skin fibroblasts from patients with PXE
have been shown to display enhanced
synthesis of elastin and glycosamino-
glycan/proteoglycan complexes, and
they also show enhanced degradative
potential because of elevated matrix
metalloproteinase-2 activity (Passi
et al., 1996; Quaglino et al., 2000,
2005). Finally, in support of this postu-
late are observations that the elastic
structures in the skin that become
mineralized in PXE do not appear
morphologically normal, and they have
been suggested to contain elastin,
which differs from elastin isolated from
normal skin (Lebwohl et al., 1993;
Sakuraoka et al., 1994).
In support of the ‘‘metabolic hypoth-
esis,’’ it has been pointed out that
clinical manifestations in patients with
PXE are rarely present in early child-
hood, the onset of clinical findings is
delayed, and the progression of the
disease is slow, as reflected by the
accumulation of calcium/phosphate
deposits in soft connective tissues of
the affected organs. Serum from
Abcc6/ mice has been shown to lack
the capacity to prevent calcium/phos-
phate precipitation in a cell-based
in vitro assay (Jiang et al., 2007).
Furthermore, serum from patients with
ABCC6-deficient liver Normal liver
Eye
Blood vessel
Kidney
Skin
ABCC6
transporter
protein
Substrate
molecule
Mineralization
Figure 1. Illustration of the proposed ‘‘metabolic hypothesis’’ of PXE. Under physiologic conditions, the ABCC6 protein is expressed in high levels in the liver
and serves as an efflux pump on the basolateral surface of hepatocytes transporting critical metabolites from the intracellular milieu to the circulation
(right side of the panel). In the absence of ABCC6 transporter activity in PXE, reduced concentrations of such substrate molecules, which may serve as
physiologic anti-mineralization factors, are found in circulation, resulting in mineralization of connective tissues in a number of organs, such as the eye, the
arterial blood vessels, the kidneys, and the skin (middle panel). The presence of mineralization is illustrated by a histopathological examination (Alizarin
red stain) of tissues in Abcc6/ mice that recapitulate the features of human PXE. (Modified from Jiang and Uitto, 2006, with permission).
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PXE, when added to tissue culture
medium of fibroblasts, has been shown
to alter the expression of elastin, again
suggesting the presence or absence
of specific circulatory factors (Le Saux
et al., 2006).
Grafting and parabiotic mouse models
We have recently addressed the ‘‘me-
tabolic hypothesis’’ by taking advan-
tage of the Abcc6/ mouse model that
recapitulates features of human PXE,
including late-onset (5–6 weeks after
the birth), yet progressive, mineraliza-
tion of connective tissues (Klement
et al., 2005). In the first set of studies,
we performed skin grafting in which
muzzle skin from Abcc6/ (KO) mice
or from their wild-type (WT) litter-
mates, was grafted onto the back of
Abcc6þ /þ and Abcc6/ mice (Jiang
et al., 2009). The muzzle skin of mice
contains vibrissae, and the connective
tissue capsule surrounding the bulb of
the vibrissae becomes reproducibly
mineralized in Abcc6/ mice at ap-
proximately 5 weeks, serving as an
early and quantifiable biomarker of the
mineralization process (Jiang et al.,
2007). When muzzle skin from WT
mice was grafted onto the back of KO
mice at 4 weeks of age, mineralization
ensued in subsequent 2 months. In
contrast, no mineralization was ob-
served in the muzzle skin from KO
mice transplanted onto the back of WT
mice. As the capillaries in the graft
regress while new vascular ingrowth
occurs from the recipient wound bed to
replace the regressing vessels, the
survival of the skin graft is dependent
on the re-establishment of circulation
from the recipient animal, and the graft
supplied by blood from the recipient
mouse (Capla et al., 2006). As the
Abcc6/ mouse skin graft did not
develop mineralization when placed
on to Abcc6þ /þ mouse, but the skin
from WT mouse showed mineralization
after grafting on to KO mouse, these
findings suggest that circulating factors
in the recipient’s blood have an active
role in the degree of mineralization of
the graft, irrespective of the graft
genotype (Jiang et al., 2009).
In another set of experiments, we
have used parabiotic pairing, i.e.,
surgical joining of two mice to create
a shared circulation between various
Abcc6 genotypic mice (Jiang et al.,
2010a). To prevent the immune reac-
tion between the parabiotic animals, all
mice were bred to be Rag1/, i.e.,
these mice lacked mature T- and
B-cells whereas granulocytes and
macrophages were intact, resulting in
‘‘non-leaky’’ severe combined immune
deficiency. Parabiotic pairing of mice
was performed at 4 weeks of age, at the
time of weaning and just before histo-
logically detectable mineralization
in the vibrissae of the Abcc6/ mice
takes place. Subsequent histopatholo-
gical observations of the mineralization
process at 8 weeks confirmed that KO
mice, when paired with WT mice,
developed much less mineralization
than KO mice in KOþKO pairs. At
the same time, WT or heterozygous
mice either in homogenetic pairings or
in heterogenetic pairing with KO mice
developed no evidence of mineraliza-
tion up to 3 months of age (Jiang et al.,
2010a). Collectively, these experi-
ments, combined with in vitro mea-
surements of the anti-mineralization
capacity of serum in KO mice, suggest
that Abcc6/ mice lack circulatory
factors that in WT mice prevent pre-
cipitation of calcium/phosphate under
normal homeostatic conditions.
PXE-LIKE CUTANEOUS FINDINGS
AND VITAMIN K-DEPENDENT
COAGULATION FACTOR DEFICIENCY
Adding to the diagnostic difficulties
related to PXE, skin manifestations
reminiscent of PXE can be found
in a number of unrelated clinical
conditions, both acquired and genetic
(Neldner, 1988; Li et al., 2009a). For
example, PXE-like cutaneous changes,
even with ocular findings, can be found
in a number of patients with b-thalas-
semia and sickle cell anemia, yet these
individuals do not harbor mutations in
the ABCC6 gene (Baccarani-Contri
et al., 2001; Hamlin et al., 2003).
Recently, particularly intriguing obser-
vations with potential pathomechanis-
tic implications for PXE have been
made in patients with PXE-like cuta-
neous findings in association with
vitamin K-dependent multiple coagula-
tion factor deficiency (Vanakker et al.,
2007; Li et al., 2009b, c). These
patients show primary cutaneous lesions
similar to those seen in PXE, i.e., small,
yellowish papules and excessive fold-
ing and sagging of the skin with loss of
recoil. These patients have been de-
scribed as having combined clinical
features of both PXE and cutis laxa
(Vanakker et al., 2007). However,
cutaneous lesions in these patients
depict characteristic mineralization of
elastic structures similar to PXE, find-
ings that are not present in patients with
cutis laxa (Uitto and Ringpfeil, 2007).
Mutations in the GGCX gene
Molecular analysis of some of the
patients with PXE-like cutaneous find-
ings and bleeding disorder has revealed
mutations in the GGCX gene, which
encodes an enzyme responsible for
g-glutamyl carboxylation of proteins,
such as the vitamin K-dependent coa-
gulation factors and matrix gla-protein
(Figure 2) (Berkner, 2005). Some of
these patients show inactivating mis-
sense mutations in both alleles of
GGCX, and clinically they show both
the PXE-like cutaneous findings and the
bleeding tendency (Vanakker et al.,
2007; Li et al., 2009c). In some cases,
the GGCX mutations are heterozygous
in combination with a heterozygous
ABCC6 mutation (Li et al., 2009b). In a
particularly illustrative family, indivi-
duals were shown to be heterozygous
for a nonsense mutation (p.R1141X) in
ABCC6 and a missense mutation
(p.V255M) in GGCX. These patients
have cutaneous findings consistent
with PXE but without any coagulation
disorder, suggesting digenic inheri-
tance of PXE in this family (Li et al.,
2009b).
The identification of missense muta-
tions in GGCX, accompanied with
PXE-like cutaneous changes and histo-
pathologically demonstrable minerali-
zation of elastic structures in the
dermis, potentially provides insights
into the pathomechanisms of classic
PXE. One postulate revolves around
vitamin K-dependent g-glutamyl
carboxylation of matrix gla-protein
(Shearer, 2000). This low molecular
weight protein has the capacity to
prevent untoward mineralization under
normal homeostatic levels of calcium
and phosphorus, as shown by the
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development of the corresponding KO
mouse, Mgp/, characterized by ex-
tensive mineralization of connective
tissues (Luo et al., 1997). However, to
be active in its anti-mineralization
function, this protein has to be in a
fully carboxylated form (cMGP), while
under-carboxylated form of the protein
(ucMGP) is inactive (Figure 2). Exam-
ination of cutaneous lesions in patients
with PXE and in Abcc6/ mice with
specific antibodies that distinguish
these two different forms of MGP has
suggested that MGP is under-carboxy-
lated in these clinical situations (Ghe-
duzzi et al., 2007; Li et al., 2007). A
potential explanation for under-carbox-
ylation of MGP in classic PXE revolves
around the possibility that the ABCC6
protein participates in transmembrane
transport and redistribution of vitamin
K derivatives, specifically its reduced
form (KH2), an obligatory co-factor of
g-glutamyl carboxylase (Borst et al.,
2008; Li et al., 2009a). More precisely,
one could postulate that KH2, espe-
cially when conjugated with glu-
tathione, which renders it soluble in
an aqueous environment, could serve
as a transport substrate for ABCC6. In
patients with PXE, the absence of
ABCC6 transporter activity could result
in the reduced concentration of KH2 in
circulation and in peripheral cells, such
as dermal fibroblasts, leading to defi-
cient g-glutamyl carboxylation of MGP
and allowing subsequent mineraliza-
tion of the adjacent connective tissues
(Figure 2). Because the concentrations
of KH2 inside the hepatocytes remain
unaffected, the g-carboxylation of vita-
min K-dependent coagulation factors
remain unperturbed and no bleeding
tendency accompanies PXE because of
mutations in ABCC6. It should be noted
that if this postulate is proven correct, it
would raise the possibility that admin-
istration of the critical form of vitamin
K or its derivatives directly into circula-
tion, bypassing the liver, might coun-
teract the progressive mineralization of
connective tissues in PXE and might
ameliorate, or even cure, this disease.
GENETIC AND ENVIRONMENTAL
MODIFYING FACTORS
As indicated above, the classic forms
of PXE are caused by mutations in
the ABCC6 gene, and well over 300
distinct mutations have been disclosed
in different families. Careful examina-
tion of the mutation database in the
context of clinical manifestations and
phenotypic variability in different fa-
milies has not provided clear-cut geno-
type/phenotype correlations (Pfendner
et al., 2007, 2008), and therefore, the
reasons for the considerable phenoty-
pic variability, both intra- and inter-
familial, are not clear.
Genetic modifiers
Recent studies examining the effects of
different genetic backgrounds on the
mineralization process in Abcc6/
mouse model have shown that, besides
the specific modulation by the haploin-
sufficiency of the Ggcx gene, the
general genetic background can delay
the onset of mineralization (Li and
Uitto, 2010). It is conceivable, there-
fore, that modifier genes may also exist
in humans and that they modulate both
the age of onset and the extent of
mineralization in patients with PXE,
providing partial explanation for the
phenotypic variability. In addition to
GGCX, recent studies have suggested
genetic modulation of PXE in humans
by a few other genes as well. For
example, single nucleotide polymorph-
isms (SNPs) in the promoter region of
the secreted phosphoprotein 1 gene
(SPP1, also known as osteopontin) were
shown to be associated with PXE,
contributing to the susceptibility to this
disease (Hendig et al., 2007). Osteo-
pontin is a major local inhibitor of
ectopic calcification that has been
associated with Wnt signaling (Vattikuti
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Figure 2. The role of vitamin K in activation of gla-proteins. Vitamin K serves as a co-factor of activation
of blood coagulation factors and matrix gla-protein (MGP) by g-glutamyl carboxylase encoded by the
GGCX gene. The g-glutamyl carboxylase activates coagulation factors (Glu-Gla); the carboxylated
forms are secreted into circulation from hepatocytes and are required for normal blood coagulation
(lower panel). In peripheral connective tissue cells, such as fibroblasts, similar activation of
uncarboxylated MGP (ucMGP) normally takes place resulting in carboxylated matrix gla-protein (cMGP),
which is required for prevention of unwanted mineralization of peripheral tissues under normal
calcium and phosphate homeostatic conditions (upper panel). It has been postulated that ABCC6 serves
as a transporter molecule transporting vitamin K derivatives, such as the reduced form (KH2) conjugated
with glutathione (GSH). In the absence of ABCC6 transporter activity in PXE, the specific vitamin K
co-factor concentrations in the serum and in fibroblasts are reduced, resulting in deficient activation of
MGP and allowing ectopic mineralization in the adjacent connective tissue to take place. (Modified from
Li et al., 2009a, with permission).
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and Towler, 2004). In other studies,
polymorphisms of the xylosyltransfer-
ase genes were shown to be involved in
the severity of the disease (Scho¨n et al.,
2006). Specifically, variations in the
XYLT were associated with higher
internal organ involvement, whereas a
specific missense variation (p.A115S)
in the XT-I gene resulted in high serum
xylosyltransferase activity, potentially
reflecting increased remodeling of the
extracellular matrix. Specific SNPs in
the vascular endothelial growth factor
gene are associated with severe retino-
pathy (Zarbock et al., 2009). Finally,
genetic variations in the antioxidant
genes are risk factors for early disease
onset of PXE (Zarbock et al., 2007).
This observation is in concurrence with
previous demonstrations that oxidative
stress may have a role in the develop-
ment of PXE (Pasquali-Ronchetti et al.,
2006; Li et al., 2008).
The role of diet
In addition to genetic modifiers, several
lines of evidence suggest that diet may
affect the severity of the disease in PXE.
First, early retrospective surveys sug-
gested that individuals with history of
extensive intake of dairy products, rich
in calcium and phosphate, may show
relatively severe disease later in life
(Renie et al., 1984; Neldner, 1988).
More recently, genetically controlled
studies using Abcc6/ mice as a
model system have shown that the
mineral content of their diet can clearly
modulate the ectopic mineralization
process (LaRusso et al., 2008, 2009; Li
et al., 2010). Specifically, magnesium
carbonate, when added to the mouse
diet in amounts that increase the
magnesium concentration by 5-fold
over that in standard diet, is able to
prevent the ectopic mineralization
noted in Abcc6/ mice (Li et al.,
2010). Conversely, an experimental
diet with low magnesium was shown
to accelerate the mineralization pro-
cess in Abcc6/ mice, as compared
with the corresponding mice kept on a
standard control diet (Li and Uitto,
2010). These findings support the no-
tion that changes in the diet can alter
the age of onset and extent of miner-
alization in PXE. These observations
also suggest that dietary magnesium
might be helpful for treatment of
patients with PXE, a notion that could
be tested in carefully controlled clinical
trials. Collectively, the evidence indi-
cating modulation of the PXE pheno-
type by genetic factors and diet support
the notion that PXE is a metabolic
disease at the genome-environment
interface (Uitto et al., 2001).
CLINICAL PERSPECTIVE: TOWARDS
TREATMENT AND CURE
As summarized above, tremendous
progress has been made in understand-
ing the molecular genetics of PXE,
since reporting of the first pathogenic
mutations in the ABCC6 gene less than
a decade ago (Ringpfeil et al., 2000).
The information on specific mutations
has been helpful in confirming the
diagnosis, which is sometimes ques-
tionable on the basis of clinical findings
only. This information has also been
helpful in providing genetic counseling
on the risk of recurrence in families
with PXE, and the mutation analysis
can be used for identification of
affected individuals before develop-
ment of overt clinical signs in families
with previous history of this condition.
Finally, development of animal mod-
els, and particularly the Abcc6/
mice, that recapitulate the features of
PXE, has been extremely helpful to-
ward understanding the pathomecha-
nistic details leading from mutations in
the ABCC6 gene to ectopic mineraliza-
tion of peripheral connective tissues. In
spite of this significant progress, how-
ever, the fact remains that there is no
effective or specific treatment for PXE at
the present.
Treatment of ocular neovascularization
Significant promise is offered by recent
attempts to treat retinal manifestations
of PXE. One of the most devastating
complications of PXE is gradual loss of
visual acuity, which can occasionally
lead to complete central blindness.
These clinical symptoms are caused
by choroidal neovascularization sec-
ondary to the angioid streaks. As
vascular endothelial growth factor is a
critical component of the neovascular-
ization process in general, recent stu-
dies have tested the efficacy of the
intravitreal injection of pharmaceutical
agents, such as bevacizumab (Avastin),
an antagonist of vascular endothelial
growth factor and inhibitor of neovas-
cularization. A number of preliminary
reports have suggested that intravitreal
bevacizumab may be a promising tool
for the long-term control of choroid
neovascularization in PXE (see Kovach
et al., 2009; Sawa et al., 2009;
Wiegand et al., 2009). At the same
time, other modalities and different
strategies to treat retinal manifestations
are being developed, including thermal
laser coagulation, photodynamic ther-
apy, and intravitreal injections of other
drugs inhibiting vascular endothelial
growth factor (Finger et al., 2009).
Development of molecular therapies
Different general approaches could be
envisioned to be helpful toward finding
a treatment, and perhaps cure, of PXE.
For example, prevention of mineraliza-
tion irrespective of its etiology could be
helpful in lessening the clinical mani-
festations of PXE. It is apparent that the
progressive mineralization of connec-
tive tissues, as for example, the miner-
alization of arterial blood vessels is
responsible for the cardiovascular man-
ifestations, and mineralization of the
Bruch’s membrane is the primary cause
of the ocular findings. One potential
way of preventing, and perhaps rever-
sing, ectopic mineralization is the
manipulation of diet. Specifically, ex-
periments using the Abcc6/ animal
model, have shown that supplementa-
tion of the diet with magnesium is able
to completely prevent the ectopic
mineralization up to 6 months of age
(LaRusso et al., 2009; Li et al., 2010).
Conversely, a diet low in magnesium
and high in phosphate was shown to
exacerbate the mineralization process
in PXE mice (Li and Uitto, 2010).
Thus, further studies examining the
precise role of different mineral com-
ponents in the diet, using the preclini-
cal animal models, might lead to
clinical trials to test the feasibility
of this approach towards treatment
of PXE.
Another potentially effective way of
preventing the ectopic mineralization
revolves around the manipulation
of anti-mineralization factors in the
circulation. One of such molecules
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is fetuin-A, a powerful anti-mineral-
ization factor that under normal phy-
siologic calcium and phosphate
homeostatic conditions is able to pre-
vent aberrant mineralization. The con-
centrations of fetuin-A both in serum of
patients with PXE as well as in the
Abcc6/ mouse have been shown to
be reduced (Hendig et al., 2006; Jiang
et al., 2007). The concept of fetuin-A
serving as an anti-mineralization factor
has been derived from observations
that genetic KO mouse developed by
targeted ablation of the fetuin-A gene
shows extensive mineralization of con-
nective tissues, particularly of the
arterial blood vessels (Jahnen-Dechent
et al., 1997). Furthermore, in an in vitro
cell-based mineralization assay system,
recombinant fetuin-A has been shown
to prevent calcium/phosphate precipi-
tation in a dose-dependent manner
(Jiang et al., 2007). These observations
then raise the possibility that increasing
the fetuin-A concentrations in the
patients’ blood may prevent excessive
mineralization. This could be achieved
by the introduction of recombinant
fetuin-A directly to the circulation of
the patients with PXE. At this point,
however, the half-life of fetuin-A is
unknown, and other issues related to
protein replacement therapy, such as
antibody formation, need to be ad-
dressed in preclinical studies. Another
potential approach to introduce fetuin-
A to the circulation could use gene
therapy or cell transfer approaches. For
example, introduction of an expression
vector containing a fetuin-A cDNA
under a liver-specific promoter has
been shown to increase the synthesis
of fetuin-A with subsequent lessening
of the mineralization in Abcc6/ mice
(Jiang et al., 2010b). Again, details of
such approaches need to be worked
out in preclinical model systems before
initiating clinical trials in patients
with PXE.
Finally, strategies aimed at regenera-
tion of liver or introduction of stem
cells with capability to differentiate into
hepatocytes, could potentially result in
restoration of functional ABCC6 trans-
porter activity. In a straightforward
manner, one would envision that liver
transplant or a partial lobar replace-
ment could result in the restoration of
the ABCC6 function. In the case of
stem-cell therapy, it appears that a
significant portion of the hepatocytes
need to be replaced to achieve a
functional ABCC6 transport system in
the liver. Consideration of all these
options has to include extensive pre-
clinical animal studies, which are
currently ongoing in several labora-
tories, as well as careful consideration
of the risk/benefit ratios. Nevertheless,
development of molecular strategies, as
exemplified by progress in the treat-
ment of other heritable skin diseases
(Tamai et al., 2009; Uitto, 2009),
hopefully provides new avenues for
treatment and eventually cure for PXE,
a currently intractable disease.
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